Home / Transcripts / RxSight, Inc. (RXST) · November 3, 2026

RxSight, Inc. (RXST) Earnings Call Transcript

November 3, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 46 min

Earnings Call Speaker Segments

Oliver Moravcevic executive
#1

Thanks, operator. Joining us today are RxSight's President and Chief Executive Officer, Aziz Mottiwala, along with Chief Financial Officer Mark Wilterding. RxSight issued its financial results earlier today for the three months that ended September 30, 2026. The press release is posted on the company's website. Before we get started, I want to note that remarks and answers to questions on today's call represent management's views as of today and will contain forward-looking and opinion statements, including predictions, estimates, plans and expectations. Actual results could differ materially from those expressed or implied because of certain risks and uncertainties. Those risks and uncertainties are described more fully in the press release we issued today and in our filings with the Securities and Exchange Commission, or SEC. Our SEC filings are available on our website or on the SEC's website. We caution investors against placing undue reliance on forward-looking statements, and we disclaim any obligation to update or revise these forward-looking statements, except as required by law. We will also discuss certain non-GAAP financial measures. Disclosures about non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that an audio replay of this conference call will be available on our Investor Relations website. With that, I'll hand the call over to Aziz.

Aziz Mottiwala executive
#2

Thanks, Oliver, and good afternoon, everyone. I've now been with RxSight for a little more than 90 days, and first off I want to say how impressed I am by the team and by what we've achieved in such a brief period. What has struck me most is the passion our people bring to our technology, their dedication to patients and their resolve to put the company in position for success over the long term. We have a solid foundation of talent throughout the organization, and I'm just as excited about the new leadership and capabilities we've brought in over the past several months. Throughout this period, I've also prioritized getting out into the field and sitting down with our key physician customers. What they've told us has been consistent, and it strengthens my confidence in RxSight's technology. They have strong faith in the advantages of the Light Adjustable Lens and in the differentiated visual outcomes that the LAL provides. These discussions have also yielded valuable insight into the ways physicians are putting our technology to use, as well as where we can do a better job of supporting their practices and encouraging wider adoption. When we last spoke a quarter ago, I outlined three initial areas of focus for myself: gaining a deeper grasp of the business, pinpointing the underlying challenges and opportunities, and figuring out where our impact could be greatest. I also promised to give more visibility into our strategy and the steps we'll take to move the business forward. Most of that first assessment is finished now, and our priorities are clear: reinforce the U.S. LAL business, push ahead with our next-generation adjustable lens pipeline, and capitalize on the sizable opportunity that comes from working with Alcon. During the past three months, we've made meaningful progress on each of those priorities, all while keeping financial discipline and creating a more efficient operating model. I'll start with the U.S. commercial business. We have a sizable installed base and a broad community of physicians who firmly believe in the value of adjustability. We have a chance to encourage deeper adoption by getting customers to engage more often and at a higher quality, by clearly explaining what LAL can do for them, by fitting it more smoothly into the way practices actually work, and by building stronger advocacy among peers. In our practices with the highest utilization, we already see a lot of these elements performing very well, and what we aim for is a model that is scalable and repeatable so that a wider set of customers can reach comparable success. To take that model and turn it into more consistent execution across our customer base, the right leadership and capabilities are needed, and we have made substantial progress in strengthening both. Most recently, we added to our commercial leadership team by appointing Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy. Each of them brings extensive leadership experience and a proven history of creating and carrying out commercial plans across a wide spectrum of ophthalmic companies. Having worked alongside Taryn previously, I have direct knowledge of the leadership and commercial skills she offers. Her rare combination of commercial leadership background and medical affairs know-how is particularly valuable at this moment, when our focus is on strengthening engagement with physicians and broadening LAL adoption further. I have been acquainted with Frank for a long time, and I have always thought very highly of his standing as an eye care leader who prioritizes customers. In the couple of weeks since we made their appointments public, a number of important customers have reached out to express their excitement about these new members of our team. That enthusiasm is something I share, and I'm eager to see the positive contribution Taryn and Frank will make working with our skilled team and our highly differentiated LAL technology. During this same stretch, we've achieved significant progress on growing our sales force, having almost doubled the team's headcount. As many of our newly hired sales representatives have gone through their first onboarding and training, I've had the opportunity to meet a great number of them, and the quality of the talent we've brought into the organization has impressed me enormously. The majority come to us with a wealth of eye care background and already have solid ties to the doctors and practices we work with. Once they complete their training and get settled in their territories, we anticipate their influence will grow gradually. The rationale for this expansion is straightforward. It enables us to interact with customers more frequently, forge closer relationships, and encourage greater LAL usage among the users we already have. This more hands-on strategy additionally provides us with further opportunities to emphasize LAL's distinctive capacity to fine-tune and customize vision following surgery, so that every patient's requirements are served more effectively—a key differentiator in a marketplace that grows more competitive by the day. Attending the latest American Academy of Ophthalmology gathering in New Orleans gave me a direct look at how much our differentiation matters. It was particularly heartening to observe the extent to which physician-led conversation about adjustability wove through the scientific agenda. One recurring message in those talks: adjustability gives physicians the ability to achieve robust, personalized visual results across a range of patient groups. Those sessions made clear that physicians keep achieving strong outcomes among patients who have undergone prior corneal refractive surgery, and they report excellent results when employing blended vision strategies. Outside of the scientific sessions, I got to speak one-on-one with hundreds of surgeons at the conference, and what really struck me was how excited they remain about LAL and the results it produces. One conversation in particular stood out: an ophthalmologist told me he had just picked LAL for his own brother, a busy attorney whose visual demands are heavy and who holds his eyesight to a very high standard. He added that his brother no longer needs glasses and is delighted with how things turned out. For me, a recommendation like that shows physicians genuinely have faith in the distinct outcomes LAL makes possible. Beyond the potential we currently see in the LAL platform, we're also moving ahead with our pipeline for next-generation adjustable lenses—concentrating on innovations meant to broaden the group of patients who can benefit from adjustability, ease the workflow, and deliver even better performance. We're also feeling good about how smoothly the launch with Alcon has gone so far. Our two teams are coordinating closely and making considerable headway. What matters most is that the first 120-day period set out in our agreement has passed, and we're keen to carry this long-term partnership onward. Combined with our current LAL platform and our next-generation pipeline, this collaboration could potentially deliver the advantages of postoperative adjustability to most patients throughout the premium IOL market. Last, across the past several months, we have conducted a thorough review of where our investment priorities lie and have honed our emphasis on running things more efficiently. Some hard choices are part of this process, and we did not make them casually. As part of that work, we recently finished a substantial restructuring that should produce meaningful cost savings in our base business while letting us put money into the areas we consider important for creating long-term value, especially our next-generation pipeline and our partnership with Alcon. With that, I will hand the call to Mark, who will give further detail and go through our third quarter financial results.

Mark Wilterding executive
#3

Thanks, Aziz, and good afternoon, everyone. Total company revenue for the third quarter came in at $24.6 million, down 19% from $30.3 million in the same period last year. LAL procedure volume brought in $22.8 million of revenue in Q3, and the remainder came from LDD and service revenue. LAL procedure volume for the third quarter was 23,128 units, an 11% decrease from 26,045 units a year earlier, mainly because of continued competitive pressures. Gross margin in the third quarter was 73.6%, versus 79.9% in the prior year period, largely due to higher inventory reserves, partly offset by a favorable product mix; in last year's third quarter, gross margin was unusually high because of sell-through of lower-cost LAL and LDD inventory. SG&A expenses for the third quarter totaled $27.4 million, in line with the prior year period. Research and development expenses were $9.2 million, essentially matching the $9.1 million reported in the third quarter of 2025. We posted a net loss of $16.2 million, or $0.39 per basic and diluted share, on 41.7 million weighted average shares outstanding. Stock-based compensation came to $7.6 million, which produced an adjusted net loss of $8.6 million, or $0.21 per share. We finished the third quarter with cash, cash equivalents and short-term investments of $254.7 million, which includes $60 million received as the upfront payment under the Alcon collaboration. Now turning to the restructuring that was discussed, I'd like to offer some added perspective on what these changes mean financially. After a thorough bottom-up review, we made changes to our cost structure and how we allocate resources across manufacturing, corporate functions and international operations. We anticipate that these actions will deliver meaningful expense savings in our base business and help support a more efficient operating model. We expect the benefit of those savings to show up in 2027 and beyond. Importantly, these savings ought to give us more flexibility to keep funding our key strategic initiatives while we manage our overall expense base. Looking ahead, we'll stay disciplined about resource allocation, steering investment toward areas where we think it can create the most long-term value. Finally, on our outlook, as we said last quarter, we aren't offering formal guidance for full year 2026. We plan to resume providing financial guidance for 2027 when we report fourth quarter results early next year; with that, I'll hand the call back to Aziz.

Aziz Mottiwala executive
#4

Thanks, Mark. We have gotten a lot done in a fairly short stretch, and I am proud of the urgency and purpose the team has shown. The steps we have taken, in my view, will make our foundation stronger and put the company in position to succeed over the long term. Those changes will pay off gradually, and there is still a good amount of work in front of us. What we are focused on right now is building up our capabilities, pushing our key strategic initiatives forward and delivering consistently across the business. We have made meaningful progress, and we plan to keep that same urgency as we move ahead. With that, I will turn it over to the operator to open the line for questions.

Larry Biegelsen analyst
#5

Aziz, I'd like to dig a bit deeper into what you're seeing across the business. On the Q2 call, I believe you mentioned you were encouraged by quarter-to-date trends and that they were broadly in line with the guidance you'd given before. It does look like conditions may have deteriorated a little. Would you say that's accurate? And if it is, what's driving it? I also heard you mention that perhaps — it sounds like you may be putting more emphasis on those post-refractory surgery patients. And I have one follow-up question.

Aziz Mottiwala executive
#6

Sure. Thanks for the questions, Larry. The way I'd frame it is by looking at what's happening in Q3 compared with Q2, and there are a few factors. One is clearly seasonality. Q3 is usually somewhat lighter than Q2, simply because of holidays. Time away from the office. We're aware of that, and it has an effect. On top of that, I'd add ongoing competitive pressure. We flagged this last quarter. I believe it's still something we're encountering in the market right now, with recent launches impacting utilization. Much of that comes from free product that's provided, sort of sample lenses. So I think we're working through it, but we certainly felt an impact from that in the third quarter. Then the third item I'd point to is that we did carry out — undertake some meaningful restructuring, obviously, with the sales force expansion, which requires territory changes. We made other changes internally within the organization that Mark and I referred to in the prepared comments. So there's definitely been some internal disruption. We've also just brought in new leadership. So I think several compounding factors played a part. Overall, I think the trend is good, though obviously not where we want it to be. What gives me a great deal of optimism and confidence is that when I look at pockets of surgeons, I actually see some of our top surgeons growing. I see some surgeons who were at the top end still driving a lot of volume. I was up in Seattle recently and visited a clinic that was celebrating their 5,000th placement of a lens from us. So there's clearly room to grow, and we see that in pockets. We just need to see it happen more consistently across the business, and that's where the strategy and the levers we're putting in place really need to take hold. You also asked about post-refractive patients. I think that's an area we hear a lot about; it's an obvious one that we should own; we're putting some efforts there, but I certainly wouldn't limit us to that. There are other patient segments that I think we can own as well. But that's one of the most obvious and clear segments that we hear about all the time from docs, and we see a lot of positive outcomes there.

Larry Biegelsen analyst
#7

And perhaps one more question for you or Mark. Any directional color you can give on Q4, and do you believe you can get back to growth in '27? And Mark, what amount of OpEx savings will the restructuring deliver?

Mark Wilterding executive
#8

Sure, Larry. It's sort of a multi-part question, but I'll walk through it with you. I'd say we're still pretty early in Q4, obviously, with October just completed, but the trends we saw encouraged us, particularly, I'd say, the ongoing confidence we hear from physicians in our technology. That said, though, I do think we expect continued competitive activity plus ongoing product trialing to affect performance through the rest of this year. I'd also prefer to err on probably the conservative side regarding the potential for disruption tied to some of the recent restructuring initiatives that Aziz mentioned earlier. So for that reason, I expect Q4 LAL sales at least to look closer to what we saw in Q2. On the restructuring initiatives, we took a really hard look at this and made some difficult decisions. And as I said in the prepared remarks, it included areas like manufacturing, corporate G&A functions, international. It was comprehensive and it was significant; we do expect these actions to produce meaningful expense savings in our base business. And by that, I mean it puts us in a position to keep making meaningful investments in our Alcon collaboration agreements in the build-out of our U.S. commercial team, et cetera. But net of that, we do think we will be in a position to achieve lower OpEx spend in 2027 versus what you'll see in 2026.

Ryan Zimmerman analyst
#9

Perhaps I'll just pick up on a few points Larry raised. First, Aziz, given the adjustments you're implementing — and I was skimming the 10-Q quickly — are you possibly pulling back internationally at this point? Should we view that as a retreat in priority toward the domestic business and the Alcon agreement? That's likely my initial question. Then I definitely want to hear your thinking on — you mentioned the 120 days. I get that this was a crucial milestone for the agreement itself. But is there anything past that which we should watch for over the coming couple of quarters on the agreement that you'd flag as a significant milestone for investors?

Aziz Mottiwala executive
#10

Yes. Thanks, Ryan. One area I care deeply about is making sure the company keeps a clear, direct focus where we execute a few things exceptionally well; and I'd say our three biggest priorities as a company are, first, to reinvigorate U.S. LAL sales; second, to drive development of our next-gen LAL internally; and third, to focus on bringing the Alcon partnership to fruition. So those are the three key priorities. On international, we'll still do some things there, a very focused, very intentional effort; but if you're asking where it ranks in the hierarchy, I think our priorities are very clear. Those first three priorities will get the vast majority of our time; that's where the vast majority of our resources will go. That will show up, as Mark alluded to, in how we think about OpEx and capital allocation next year. So what lets us bring OpEx down year-over-year is simply having that shared focus. On the Alcon agreement specifically, the 120-day mark mattered a great deal because it means the upfront payments are solidified and cannot be clawed back from Alcon; so that truly cements our ability to move forward and lets us account for that upfront payment on our balance sheet. So it's a very big deal; regarding the progress we're making, I think the teams have met together a handful of times already. Discussions are robust; we're making great progress. As for those milestones, I'd expect us to provide a bit more color on some key steps and milestones when we get into '27 guidance; so I think of that as a comprehensive event where we give revenue guidance, OpEx guidance as well as other milestone guidance regarding our internal pipeline and the Alcon collaboration. So early days, but everything we're seeing is really positive; and clearly, getting past the 120-day milestone and solidifying the path forward is a great achievement for us and one we're really looking to build on from here.

Ryan Zimmerman analyst
#11

Okay. That's really useful. If I may fit in one final question. You've now done two rental agreements on the LDD side — not that anyone's counting, of course — but it does complicate the ASP figures when we attempt to model them. I'm just curious, Mark, how should we think about ASPs on the LDD side — are they holding steady, or should we view them somewhat differently? Any color you can offer would be appreciated.

Mark Wilterding executive
#12

Yes. Thanks for asking, Ryan. In the third quarter we had three sales and one rental. On the ASP front, stability looks very good. Nothing meaningful has shifted compared with the historical pattern you've observed. The rental option appeals to us; our focus has always been on giving customers a range of choices, and we want to see adoption of this therapy grow. A one-size-fits-all approach isn't something we take, and we never have. So I think you should expect the possibility of more of those. And from our customers, I believe we've also gotten good feedback that they like them too.

David Saxon analyst
#13

Let me begin by revisiting a few points you raised, Aziz, when Larry asked about those pockets of strength. Is there something distinctive — or, I suppose, unique — about the physicians in those pockets that is fueling the momentum you're seeing? Is that more or less where you kicked off some of these recent efforts? Or do you have any insight into what is driving those pockets of strength and whether what's happening there might be replicated elsewhere?

Aziz Mottiwala executive
#14

Yes. I devote a lot of time to this — examining what we're seeing and what those areas of strength can teach us. And there are some, right? We're seeing several cases with quite encouraging patterns and useful takeaways emerging. First, a key observation is that our strongest accounts usually receive more frequent visits from our people. We can simply reach them more often—which is part of why we grew the team, enabling us to cover additional accounts that way. Second, I notice the practice integration. We've put substantial investment and effort into those clinics—refining the workflow, collaborating with their staff, and providing training. In the specific practices and regions where results have been robust, our execution has been excellent. Part of that is constrained by staffing levels, as I mentioned; and what we aim to do now with the larger sales force is broaden those efforts, then take the lessons from what succeeded in those clinics and apply them across most of our installed base. The two most significant takeaways for me, especially from being in the field and speaking with physicians at the recent academy meeting, are that they encounter us frequently and that we devoted considerable effort to that practice integration—those two factors are truly essential. They are also highly data-savvy. They understand the data extremely well. They know how this performs. We have managed to share that within their own practice, so there are several elements we can take and then extend across the entire audience. That forms part of the holistic strategy we are examining. With the proper headcount now deployed in the field, we can provide those people with the correct messaging and the correct tools so they can carry out those strategies. So I'm hopeful those developments will occur. And once you observe those solid results along with those practice outcomes, I believe you'll recognize that this is replicable across a wider base, and that's what we hear in conversations with physicians; they simply require the support. They continue to ask for it. There's a wish on their side to use more. Our role is just to support them and supply the resources required to make that happen.

David Saxon analyst
#15

All right, great. My follow-up question concerns LDD placements. You had a handful during the quarter with the rental. I mean, a few remarks in the script make it seem as though you're concentrating more on driving utilization of the installed base you already have. So I'm not requesting a figure for next year, but when we consider how the strategy evolves, will it inherently be far less centered on placing LDDs, whether through sales or rentals? And should we instead be thinking about merely adding a handful or so, in my words, not yours, each quarter?

Aziz Mottiwala executive
#16

Yes. So maybe I'll begin by giving some background on how we think about this strategically, and then let Mark speak to some of the numbers here. Strategically speaking, our main focus is on driving LAL utilization within the installed base we currently have. We have a tremendous installed base. We can grow and drive lots of volume with that installed base; and in fact, we've concentrated our resources on driving LAL. So whereas previously a lot of resources were put against LDD placements, we've now allocated a lot of those resources to LAL performance, and primarily LAL performance; so it doesn't surprise us that we're seeing lower volumes of LDD, and I'd expect that to be the case going forward, where these placements are much more strategic and thoughtful in nature. I'll let Mark speak to the actual numbers and trends and how the rental agreements were put into the accounting there.

Mark Wilterding executive
#17

Yes. Nicely put, Aziz — I’m not sure there’s much more for me to add there. But as you said, our main focus is definitely on getting growth going again in LAL procedures. So because of that — and this is kind of, I think, where you were headed, David — I would expect LDD sales to be fairly limited going forward, just a handful, as I believe you phrased it.

Alan Liang analyst
#18

Alan here, covering for Robbie. I'd like to go back over the top-line trends we saw this quarter. I understand seasonality is certainly a factor worth watching. Still, if you look only at the year-over-year numbers, it genuinely appears that after things stabilized somewhat in 2Q, you took another step down during the third quarter. Has anything changed when it comes to competition? I'm aware you brought up disruption caused by internal restructuring. Could you just help us grasp what shifted that produced a larger-than-normal sequential decline?

Aziz Mottiwala executive
#19

Yes. I believe — Robbie, pardon me, Alan, thank you for asking. In my view, three things are stacking on top of each other: the usual seasonal pattern, ongoing pressure from competitors, and the internal restructuring and disruption we've been through. Being able to grow the team is a positive, but it means territories have to be redrawn. It also takes time away from selling — time spent on training and onboarding instead of being in the field. A considerable share of our sales managers' attention went toward recruiting. It's no shock that some disruption will show up there. I'd call that short-term discomfort that positions us for success over the long haul and points the business toward where it needs to be going forward. That's definitely a piece of reworking both the commercial strategy and the commercial infrastructure here. Still, if you're breaking down what the factors are, I'd say those three are the primary drivers.

Alan Liang analyst
#20

Understood. And I realize you aren't giving guidance, but looking ahead, would you say most of that effort is now behind you, so you can concentrate on simply executing and driving the LAL adoption you mentioned? Or does more work remain?

Mark Wilterding executive
#21

Work is never finished, I'd say, correct? This is an ongoing thing, in my view. Some of the recent hires we've brought on certainly encourage us, but the question now is getting those people trained and out in the field, and we want to factor that in as we look toward next year. So that could definitely require some time. Aziz, I don't know whether you'd like to add anything further to that.

Aziz Mottiwala executive
#22

No, I think this is all right.

Young Li analyst
#23

So I guess I'd like to dig a bit deeper into the U.S. sales force nearly doubling — clearly that arrived sooner than we expected. I'm curious whether you could expand a bit on the changes being made there. Is there any attrition among existing reps, any shifts in territory and accounts? And is there anything else you can share on that?

Aziz Mottiwala executive
#24

Sure. Thanks for asking, Young. It's a fairly major rework of the commercial infrastructure, when you think about it, since a lot of resources previously dedicated to LDD are being shifted. We're moving into LAL. That means we have to remap territories and fully reorient customer alignment. So doubling the team is a fairly significant undertaking; we invested a lot of time making sure we recruit high-quality talent from across the industry; and as we said in the prepared comments, I'm really pleased with the caliber of talent coming in the door. Nearly every person we bring in has strong eye care experience and existing relationships. So that will help translate over time. But again, we did see a lot of disruption in the quarter because we are moving things around and spending a lot of time recruiting. As you said, we did that in a pretty rapid fashion, which obviously affected our ability to be in front of customers, but it's the right thing to do to get us in the right orientation and the right structure so we can move forward and start executing on the long-term strategic plan here.

Young Li analyst
#25

Okay, that's great, and very useful. So I suppose this is something of a follow-up on that point. Could you walk us through some of the operational rigor or sales discipline efforts you've got underway? In essence, what's different in that area compared with what you were doing before?

Aziz Mottiwala executive
#26

Sure. Our approach to sales force execution has become far more driven by data and analytics, with much more measurement of how often we're actually in front of customers. We are segmenting the customer base. I believe that will carry through when we get to '27 guidance, where we'll discuss what the key performance indicators, our KPIs, will be as we aim to rebound this business, in terms of utilization depth by surgeon, by cohort, and we'll probably offer some color on how we view certain of those segments and where growth can come from. All of those are ways we now measure our effectiveness; so, as I said earlier, we are seeing pockets of good performance; we just need to translate that across the business. So there's a great deal of operating rigor and a data-driven approach in how we execute commercially; and I'd say the other area Mark is really overseeing here is genuine operational rigor around capital allocation. And I give Mark and his team a lot of credit for helping lead our restructuring and OpEx initiatives here. As he said, this is a big deal. Next year we'll be able to bring our OpEx down pretty significantly from 2026, and that's while investing incrementally in a larger sales organization over time as well as the Alcon development and the LAL next-gen platform development. So those are all incremental areas year-over-year. But even with those incremental expense areas, our total OpEx will come down; so that demands that we be really sharp and really diligent, demands that we be really smart about where every single dollar goes and simply have a different level of operating rigor when it comes to capital allocation. So that's a big commitment on our side as well.

Steve Lichtman analyst
#27

Aziz, when you consider those practices that are performing well, one factor you mentioned is a robust presence from RxSight sales reps. You've obviously grown the sales force, but I'm curious how you continue driving those efforts into new practices without utilization dropping elsewhere. To phrase it differently, how lasting can these changes be without needing the same degree of sales force intensity?

Aziz Mottiwala executive
#28

Excellent question. A lot of this hinges on focusing on our installed base; we have many physicians who are trained, who can access an LDD and are achieving decent volumes of LAL. Being in front of them more often should help us boost how much they use. We deliberately shaped the sales force’s size and structure to reach the wide base of our installed base with high frequency. That way we can be in front of every key customer we need to see as often as required. My sense is that the large majority of the effort will center on those existing accounts. Going forward, the surgeon base will expand somewhat, and we have factored that in. What we're banking on is expansion from surgeons already with us, not just depending on new ones. Previously, I think LDDs and incoming surgeons drove things; we simply never made the commitment to our current surgeons to carry them beyond what I'd describe as that baseline utilization toward those high thresholds. In some pockets we did commit, and where we have, utilization looks really strong. That utilization continues to climb. So, in response to what you asked: when you pass a certain point, we really notice a lot of staying power in those practices—the ones reaching more than 1,000 implants since launch, or 2,000 implants over launch. But it does take time and effort to cultivate that relationship with the practice, to help establish solid workflow patterns, and to keep educating the whole staff. That's the focus we have now, given the size of our team. I believe we can cover our full installed base, handle the incremental surgeons who come in, and accomplish that at the right cadence while building the right durability underneath it.

Steve Lichtman analyst
#29

Understood, that helps. Just to follow up — and sorry if I overlooked this — what are your thoughts on the broader market? I know cataract volumes were weaker at the start of the year. Are you noticing any improvement? And do premium procedures remain fairly resilient?

Aziz Mottiwala executive
#30

For the most part, I'd describe things as slightly soft, though not dramatically so. The bigger dynamic in the marketplace right now, I think, is likely just competitive pressure from new installs. What you're seeing, I believe, is a lot of trialing — in other words, plenty of free product entering the market. So that's weighing on volumes, but overall surgical volume, or patient flow, has come back a little since the start of the year. I wouldn't describe it as robust, but I'd say it's more stable than, say, the first half of the year, when we definitely felt an impact from weather, some economic uncertainty, et cetera. I think it's TBD where that goes for the rest of this year and into next, but I'd say it's been relatively stable in Q2 and Q3.

Adam Maeder analyst
#31

I'll stick to just one multipart pipeline question. Looking through the slide deck, it appears the next-gen LAL, if I'm reading the timeline right, gets approval in 2028. So I wanted to check whether you can confirm that's right. And then perhaps just walk through what it takes to bring that product to market, along with some of the features of that technology. That's all from me.

Aziz Mottiwala executive
#32

Yes. We haven't yet provided a specific date for the approval target. What I'd take from that, I think, is that 2028 is the soonest we could see it, since there's a fair amount of work still to do there. On the features and benefits of next gen, I'd say three really stand out to me. First is being able to offer this to more patients, right? We're thinking about opening up the aperture, no pun intended, to a bigger segment of patients. Second, something I know many surgeons are excited about, is cutting down workflow and cutting down the number of visits for a lock-in so that it becomes even more efficient; that's a major feature here. And third is simply some design elements that make this a bit friendlier during the surgical process. The lens is somewhat unique. So some of the design elements we can incorporate will make it even more intuitive for surgeons and hopefully improve that user experience further. So those are the three things we're looking at. Obviously, we're building that lens. We'd need to take it from proof of concept into the clinic and so on and do the proper testing. So I'd imagine we'll give a bit more color on that again in '27 when we provide guidance and offer some color on what those specific milestones will be and how we'll track toward approval, and potentially provide a bit more specificity on when we expect that to reach the market. But we're making great progress, and it could be a huge opportunity for us to reinvigorate and add another complement to the LAL portfolio.

Stephanie Piazzola analyst
#33

With the LAL utilization numbers and current status now on the table, I want to turn to the assessment stage: what did you identify as the main barriers to raising LAL utilization? And what portion of that is something a commercial change can solve, as opposed to issues that are more structural? Also, perhaps, what has customer reception been like, and how easy or difficult is it for them to implement some of these changes in order to grow LAL utilization?

Aziz Mottiwala executive
#34

Yes. Thanks for the question. I would say that nearly all the challenges we have faced commercially are things the new commercial strategy can address. Nothing in the market, structurally speaking, stands in the way of us accomplishing that. When I speak with surgeons, the two things I hear most often are: first, they love the technology and want to use more of it; second, they simply don't see enough of us. That's really the heart of the matter. And of course, when you dig deeper, what comes up is, well, I need support setting up the workflow and training my practice so it can handle that workflow. I need clearer direction on which patients are the right ones, and on when they should choose your lens rather than a competitor's lens. All of those are things we can tackle with the right commercial strategy. To my mind, the three points I'll concentrate on here are, once more, frequency—simply being in front of the customer often enough; that's one of the things we hear loud and clear. Our competitors are there all the time. With this new sales force structure and design, I believe we'll manage to keep a higher share of voice and be more present. And that will let us not only remain top of mind but also embed ourselves in the practice, assist with that practice integration, and help train the staff so the volumes get pulled through. Beyond that, we need to be capable of holding substantive conversations with the practice and the surgeon regarding which patients are ideal, and when LAL should be chosen rather than a rival lens. LAL offers clearly distinct advantages for particular patient groups, and we simply cannot communicate those advantages when we aren't face to face with the customer—so we must make that happen. We must do so often, and we must do so reliably, and over the past several quarters we have managed none of these. I feel confident that once the team settles in—with training and onboarding finished and everyone out in the field—we'll begin to see that growth accumulate over time, establishing those relationships along with the frequency and durability we're after. I believe an earlier question asked whether durability will hold here, and I think two points deserve emphasis. First, every one of these matters is something I believe we can address by strengthening our commercial output. Second, if we handle it properly, those results are going to last for the business over the long term; and all of these are investments we're making, in my view, not just for the near-term LAL portfolio, but they'll also pay off for us when it comes to our next-gen lens and are highly relevant to the Alcon opportunity as well. Let me use this moment to stress how significant that is, right? Here's a pipeline opportunity to bring adjustability to the mass side of the market, right? The overwhelming majority of patients sit in the premium segment. How well we do right now at teaching surgeons, bringing them aboard, and embedding them into their practices to carry out adjustments will determine how much success we achieve with our partner when those products eventually arrive, since that moment would give us an opportunity to serve essentially the entire premium market. The payoff could be substantial provided we act correctly in the present—planting seeds in the market and genuinely making adjustability the accepted standard of care.

Stephanie Piazzola analyst
#35

Next, I'd like to ask a follow-up about competition. You mentioned samples and trialing as a big source of the pressure you're facing. I'm curious whether you could elaborate on what you're hearing in the field on the competitive front? And also, what gives you confidence that this is perhaps temporary sampling rather than an improvement in competitive IOL technology?

Aziz Mottiwala executive
#36

Yes. I think when doctors talk to us, many of them say they're getting free lenses to try the product, and that's the biggest impact you see, right? Because obviously they're going to use lenses that are going to be comped. I think that behavior is expected. As you start to scale the experience and examine data across these products, I'd say that when you look at the clinical data for any of the new IOLs, all of them represent, in my view, modest improvements over what's currently offered. So continued innovation in this space is great. I'd say nothing has been as profound as what we've accomplished with the light adjustable lens. And when we look at the outcomes we can deliver — the percentage of patients who are spectacle-free, the percentage of patients with great distance vision — it's really unparalleled. Confidence on our side stems from demonstrated results achieved across the past several years. The information available to us is considerably stronger. Once more, the key is simply gaining access to those offices to discuss it, and clearly we require an improved approach. What I would say is this: regarding competitive dynamics, I believe we fell short in how we readied ourselves. That, in my view, is one component of our broader commercial strategy. We have to be somewhat tougher and somewhat more proactive — leaning in ahead of rivals' launches — so we truly secure our own space for LAL and ensure that position holds up better and endures. That is therefore something the commercial team, including the fresh commercial leadership, is keeping front and center.

Tom Stephan analyst
#37

First, a quick clarification before we begin. Mark, on 4Q LAL revenue, just to be sure, did you say it would be closer to 2Q or to 3Q? And if it was 2Q, I believe that suggests roughly high single-digit sequential revenue growth, which would be solid. So what gets you there given the competition, organizational disruption, and so on? Then I have a follow-up.

Mark Wilterding executive
#38

Yes, Tom, sorry if I wasn't clear. I did say Q2; and so I think your math is right, up in the mid- to high single-digit range. A big chunk of that, I'd say, comes from the fact that we don't really see much seasonal swing between Q3 and Q4, and the trends we've been seeing so far this quarter in October also give us confidence on that front.

Tom Stephan analyst
#39

Perfect, that's really helpful. Then, Aziz, maybe this one's for you — I'd like to return to competitive pressures. Suppose we're talking about J&J's PureSee; on that lens, what our checks indicate is that surgeons are using it, I'd say, with a fair amount of confidence, and more so in that post-refractive patient population, which has definitely been one of your moats — one of LAL's moats. Are you also seeing early signs of this? And/or does this become a risk down the road if EDOF lenses specifically as a category, for instance with Vivity Pro on the way, start to encroach on that post-refractive market for you — again, especially as those lenses continue to innovate and improve.

Aziz Mottiwala executive
#40

Yeah, Tom, hearing that, my read is it's likely more about experimentation and trials with those patients. I wouldn't call it the go-to lens. I don't believe people are switching to EDOF as their go-to. For the great majority of post-refractive patients, LAL remains the main go-to, in my view; and I think we can keep building on that, since we have strong data backing it up. What you'll see, I'd say, is some trialing. Naturally, when new lenses launch, people will explore various patient types. That's what I'd expect, but I don't expect it to shift the standard, and that isn't what we're hearing. We do hear that some trialing is happening in those patient types, yes. What we aren't hearing, though, is a wholesale shift in how physicians think about that segment. And remember, that segment is quite diverse—so these might be post-refractive patients, perhaps at the lowest risk for any complication. If you consider a more significant patient type, that's clearly an LAL patient; and I do believe there's more we can do—to borrow your phrase—to secure that moat, and that's part of our competitive strategy, right, how to secure that moat and potentially build on it so we can even expand into other patient types where LAL is the better option for those patients. I wouldn't characterize that as a complete overhaul. Some of those patients will likely go through a bit of trial and error, in my view. Still, that strikes me as a space where we can concentrate our resources effectively to establish a durable advantage and then grow outward from that base.

Operator operator
#41

There are no further questions at this time; and this concludes today's call.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete RxSight, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to RxSight, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.